ATRX and astrocytoma (excluding glioblastoma): Importantly, in the group of molecular astrocytoma, patients with ATRX loss had a significantly better outcome than patients without ATRX loss, thus providing evidence that the molecular profile helps to refine the prognosis in malignant glioma patients.